INTRODUCTION
============

Inflammatory bowel disease (IBD) refers to a group of chronic inflammatory disorders that affect the GI tract \[[@b1-ir-2019-00091]\]. IBD is divided into 2 main clinical types: CD and UC. CD can occur in any part of the GI tract, commonly in the ileo-colonic region, but it can also affect the upper GI tract.

According to the European Crohn's and Colitis Organisation, no standard diagnostic reference exist for the diagnosis of CD; diagnosis is based on a combination of clinical, endoscopic, and histological features \[[@b2-ir-2019-00091]\]. Upper GI CD (UGICD) is uncommon in adults, occurring in 0.3 to 5% of adult patients with CD \[[@b3-ir-2019-00091]\]. Conversely, it has been found that 28% of adolescents and 43% of pediatric patients with CD have UGICD \[[@b4-ir-2019-00091],[@b5-ir-2019-00091]\]. This variation between adult patients and adolescents and pediatric patients could be explained by the variation in the practice of diagnosing adult and pediatric patients with CD. Pediatric gastroenterologists tend to perform upper endoscopy more often than adult gastroenterologists during the evaluation of patients for possible CD diagnosis, in accordance with the recommendations of the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) revised Porto criteria \[[@b6-ir-2019-00091]\].

The incidence of foregut CD has been reported in 40% of adult patients who had prospective upper endoscopy after confirming the diagnosis of CD, and only 32% of the patients experience symptoms \[[@b7-ir-2019-00091]\]. Endoscopic abnormalities of the upper GI tract including mucosal erosions, aphthous ulceration, and mucosal thickening have been reported in 56% of adults with CD \[[@b8-ir-2019-00091]\].

A diagnosis of CD of the upper GI tract is carried out by a combination of clinical, endoscopic, and histological features \[[@b9-ir-2019-00091],[@b10-ir-2019-00091]\]. The histopathological examination of the biopsies acquired from the lower esophagus, stomach, and the duodenum of CD patients with an endoscopically normal upper GI tract may reveal pathognomonic CD lesions \[[@b11-ir-2019-00091]\] and since granulomas can be found in variety of conditions involving the GI tract, exclusion of such conditions is required before accepting the presence of non-caseating granulomas as the histological proof of CD \[[@b9-ir-2019-00091]\].

The confirmation of the presence of UGICD in patients with CD is of prognostic value. Patients with UGICD manifestations are at higher risk of more aggressive stricturing and a more penetrating form of the disease, meaning more recurrences, frequent hospitalization, and more surgical interventions \[[@b12-ir-2019-00091]\].

Studies addressing the subject of UGICD in Saudi patients are lacking, therefore this study aimed to determine the prevalence and clinical characteristics of UGICD in a cohort of Saudi patients, and to identify significant clinical predictors of UGICD.

METHODS
=======

The King Abdulaziz University Hospital (KAUH) Inflammatory Bowel Disease Information System (IBDIS) registry was utilized to conduct a retrospective analysis. The IBDIS registry is a web-based database that has been used to register IBD patients following up at KAUH since January 2018. IBDIS contains demographic, clinical, endoscopic, laboratory, radiological, and endoscopic data. The hospital electrical medical records were also accessed for supplementary data. We first went through our IBD database and isolated patients with confirmed CD rather than UC, then we identified those from this cohort who had upper GI endoscopy at baseline, following this we started to collect the relevant data. All patients diagnosed with CD prior to 2017 that underwent upper GI endoscopy with biopsies were identified in IBDIS and included in this analysis with no age restrictions. Diagnosis of CD was based on standard clinical, endoscopic, and histological criteria 2.

1. Inclusion Criteria
---------------------

All patients with a confirmed diagnosis of CD who had simultaneous upper GI endoscopy performed at the time of diagnosis were included.

2. Exclusion Criteria
---------------------

Patients with a known diagnosis of gastroesophageal reflux disease/esophagitis and patients with known peptic ulcer disease, active *Helicobacter pylori* infection or patients on NSAIDs were excluded. Patients with confirmed tuberculosis or those who received corticosteroid treatment prior to endoscopy were also excluded.

3. Endoscopic Evaluations
-------------------------

Upper GI endoscopy procedures without chromoendoscopy or image image-enhanced endoscopy were performed by experienced gastroenterologists under general anesthesia for children or conscious sedation for adolescents and adults simultaneously with ileocolonoscopy at the time of diagnosis for all patients. Multiple biopsies were regularly taken from the esophagus, gastric body, gastric antrum and second part of the duodenum. Additional targeted biopsies were performed if abnormal lesions were found. Rapid urease test (CLOtest) was routinely performed on biopsy specimens taken from the gastric antrum as an initial screening test for *H. pylori* prior to histopathological identification.

4. Histologic Criteria for UGICD
--------------------------------

The histological diagnosis was determined according to the European consensus on histopathology of IBD \[[@b13-ir-2019-00091]\], and the British Society of Gastroenterology guidelines in reporting IBD biopsies \[[@b14-ir-2019-00091]\]. The microscopic findings in the esophagi that were considered diagnostic for CD included: increased intraepithelial lymphocytes, focal infiltration of the lamina propria by mononuclear inflammatory cells, and histiocytes with or without formation of non-caseating granulomas. The findings of the gastro-duodenal biopsies included: granulomatous gastritis and focally enhanced (active) *H. pylori* negative gastritis, or a large number of macrophage aggregates, seen throughout the lamina propria \[[@b5-ir-2019-00091],[@b15-ir-2019-00091]\]. All histopathological specimens were reviewed and reported by an experienced and certified GI pathologist with special interest in IBD. We did not rely on central pathological diagnosis for inclusion into this study.

5. Outcomes
-----------

The prevalence of histologically confirmed CD in the esophagus, stomach, or duodenum was considered the primary outcome of this study. Secondary outcomes included identifying clinico-demographic predictors of upper GI tract CD.

6. Statistical Analysis
-----------------------

Descriptive statistics were applied to the raw data: for quantitative variables, means, SD, and minimum and maximum values were obtained; for qualitative variables, we used frequency measurement. The prevalence of upper GI tract CD was calculated. Chi-square and Fisher exact tests were used to delineate the relationship between patients' demographic and clinical features and upper GI tract CD, based on a *P*-value of \< 0.05. Analyses were made using SAS version 9.4 (SAS Institute, Cary, NC, USA).

7. Ethical Oversight
--------------------

Ethical considerations in accordance with the Declaration of Helsinki were followed throughout this study. This study was approved by the Research Committee/Biomedical Ethics Unit at King Abdulaziz University (Reference No. 398-17). All patients signed an informed consent prior to the endoscopy procedures that were performed for diagnostic purposes.

RESULTS
=======

1. Baseline Characteristics
---------------------------

A total of 135 patients with CD were identified in IBDIS, but only 78 patients (57.8%) fulfilled the study criteria and underwent upper GI endoscopy between 2012 and 2017. Forty-three patients (55.1%) were males with a male to female ratio of 1.2:1 and the overall mean age was 17.2 ± 8.7 years (with a range of 3--52 years). Extraintestinal manifestations of CD were reported in 17.9% of all patients (n = 14) and in 14% of patients (n = 8) diagnosed aged 18 or younger. Overall, 35.9% (n = 28), 33.3% (n = 26), and 30.8% (n = 24) had ileal, colonic, and ileo-colonic disease, respectively. The most common pattern of disease behavior was non-stricturing, non-penetrating disease (B1; 87.2%), followed by stricturing (B2; 9.0%), then penetrating (B3; 3.8%) disease. Perianal involvement (P) occurred in 10% of cases.

The most frequently reported symptoms at baseline were diarrhea (72.0%), abdominal pain (65.4%), weight loss (56.4%), and fatigue (50.0%). Other less common symptoms included vomiting (26.9%), aphthous stomatitis (10.3%), joints pain (12.8%), and eye inflammation (3.8%). Only 2 patients (2.6%) reported having dysphagia. Thirty-one percent of the sample developed complications of CD: malnutrition (19%), strictures (11.5%), and fistula (10.3%) were most common. Others encountered complications including bowel resection (9%), abscesses (5.1%), and bowel perforation (3.8%). Only 6.4% of patients reported a family history of CD and 23% had a history of parental consanguinity (parents are first-degree cousins) that may suggest genetics association with disease occurrence. All baseline characteristics are summarized in [Table 1](#t1-ir-2019-00091){ref-type="table"}. We did not encounter any patient in our cohort with symptoms of chest pain or sore throat at the time of performing diagnostic endoscopy.

2. Study Outcomes
-----------------

Nineteen patients (24.4%) had histologically confirmed UGICD. Three (3.8%), 16 (20.5%), and 9 patients (11.5%) were located in the esophagus, stomach, and duodenum, respectively ([Table 2](#t2-ir-2019-00091){ref-type="table"}). The upper GI endoscopic examination of all patients with UGICD showed normal looking mucosa in the esophagus, stomach, and duodenum in 84.2%, 15.8%, and 63.2%, respectively, in addition to various other abnormalities such as erythema, erosions, aphthous ulcerations, and stricture formation that are summarized in [Table 3](#t3-ir-2019-00091){ref-type="table"}. Confirmed histopathological abnormalities included chronic active esophagitis (15.8%), chronic active gastritis (52.6%), focal enhanced gastritis (31.6%), chronic active duodenitis (36.8%), focal chronic active duodenitis (10.5%), villous atrophy (5.3%), and duodenal non-caseating granuloma (5.3%) ([Table 4](#t4-ir-2019-00091){ref-type="table"}). The histopathological features of focal enhanced gastritis and duodenal non-caseating granuloma are depicted in [Figs 1](#f1-ir-2019-00091){ref-type="fig"} and [2](#f2-ir-2019-00091){ref-type="fig"}, respectively. Ten of the 19 (52.6%) patients with UGICD had upper GI symptoms. Nausea and vomiting were reported by 9 patients (47.4%), epigastric pain by 6 (31.6%), dysphagia by 2 (10.5%), and aphthous stomatitis by 2 (10.5%). There was no significant differences demonstrated between patients with and patients without upper GI symptoms with regards to baseline characteristics, endoscopic, or histopathological findings ([Table 5](#t5-ir-2019-00091){ref-type="table"}). The prevalence rate of UGICD according to the age of 18 years or younger versus older than 18 years was 24.6% and 23.8%, respectively.

Upon stratifying UGICD involvement according to patient age ( ≤ 18 years vs. \> 18 years), no significant difference was observed between the 2 groups (*P*= 1.0) with regards to the prevalence of UGICD. Also, there were no significant differences observed between the 2 groups with regards to the frequency of involvement of the esophagus, stomach, or duodenum ([Table 2](#t2-ir-2019-00091){ref-type="table"}).

Bivariate analysis ([Table 6](#t6-ir-2019-00091){ref-type="table"}) showed no significant association between UGICD and sex, age at diagnosis, extraintestinal manifestations, or complications. However, the association between UGICD and the disease localization demonstrated a statistical trend that did not reach statistical significant (*P*= 0.07) as ileal location was the most predominant in UGICD (57.8%) compared to 28.8% found with non-UGICD patients. The disease behavior did not differ significantly between the UGICD and non-UGICD groups (*P*= 0.77).

Patients with UGICD had comparable rates of surgical resections (2/19 \[10.5%\] vs. 5/59 \[8.5%\], *P*= 1.0) and fistulizing disease (3/19 \[15.8%\] vs. 5/59 \[8.5%\], *P*= 0.2) in contrast to patients without UGICD. No significant differences in the frequency of intestinal/colonic strictures (*P*= 1.0) or bowel perforations (*P*= 1.0) were observed. One (5.3%) patient with UGICD developed an esophageal stricture and one (5.3%) developed a gastric antral stricture that required treatment with corticosteroids intralesional injections and endoscopic balloon dilatation.

DISCUSSION
==========

The ability to accurately estimate the prevalence of upper GI involvement of CD in adults is a challenging task, mainly because adult CD patients do not undergo routine diagnostic upper GI endoscopy unless they are symptomatic. A study in adults of prospective upper GI endoscopy in patients with CD found UGICD in 41% of the patients; only one-third of them were symptomatic \[[@b7-ir-2019-00091]\]. Another study found that 56% of adult patients with CD had UGICD when upper GI endoscopy was performed \[[@b8-ir-2019-00091]\]. Studies in adolescents and children who had simultaneous upper GI endoscopy at the time of diagnosis reported a prevalence of UGICD of 23% and 36%--53%, respectively \[[@b4-ir-2019-00091],[@b16-ir-2019-00091]-[@b18-ir-2019-00091]\]. Of the patients in our study cohort who had simultaneous upper GI endoscopy at baseline, the overall prevalence of UGICD was 17.5% for children and adolescents, and 31.3% for adults, consistent with previous reports. Our patients' age were skewed towards pediatric and adolescents, who constituted 73.1% of the cohort. The predominance of children and adolescents could be attributed to the recommendations made by the ESPGHAN revised Porto Criteria to perform upper GI endoscopy with ileocolonoscopy for all patients evaluated for possible IBD \[[@b6-ir-2019-00091]\].

CD gastritis is the most common form of UGICD that occurs in 50% at the initial presentation. It is often associated with CD duodenitis; therefore, it is referred to as "gastro-duodenal CD." \[[@b19-ir-2019-00091],[@b20-ir-2019-00091]\]. Gastro-duodenal CD was the most common form of UGICD in our cohort in both children/adolescents and adults ([Table 2](#t2-ir-2019-00091){ref-type="table"}). It is associated with distal small bowel and colonic involvement in all patients, in agreement with previously reported literature \[[@b20-ir-2019-00091]-[@b22-ir-2019-00091]\]. We observed no cases of isolated gastro-duodenal involvement, which has been reported in less than one-third of patients and often evolves into distal disease \[[@b20-ir-2019-00091],[@b21-ir-2019-00091]\]. Gastro-duodenal CD can be complicated by progression to fistula formation, stricture, or both \[[@b20-ir-2019-00091],[@b22-ir-2019-00091]-[@b24-ir-2019-00091]\]. One patient in this cohort developed a gastric antral stricture, and as a consequence gastric outlet obstruction that was managed by endoscopic balloon dilatation, trans-pyloric enteral feeding, and corticosteroids treatment; none had gastro-duodenal fistulae.

Esophageal involvement, which is the rarest form of UGICD that has been reported to affect 3.3% to 6.8% of adults and 7.6% to 17.6% of children and adolescents, respectively, was found in 15.8% of our UGICD patients \[[@b5-ir-2019-00091],[@b25-ir-2019-00091]-[@b28-ir-2019-00091]\]. The main challenges in the diagnosis of UGICD arise owing to the similarity between CD esophagitis and other common conditions such as reflux and eosinophilic esophagitis, which can cause symptoms that, resemble those for CD esophagitis. The presence of nonspecific histological findings also seldom makes the distinction very difficult. Twenty-one percent of patients with CD esophagitis also have gastro-duodenal or ileo-colonic disease \[[@b25-ir-2019-00091]\]. All our patients had associated distal small bowel and colon CD disease. As with gastro-duodenal CD, patients with CD esophagitis may develop a complicated pathology, including the progression to strictures and fistulae, which is very rare. However, the majority of patients with UGICD have inflammatory CD esophagitis \[[@b25-ir-2019-00091],[@b29-ir-2019-00091]\]. Only one patient in our cohort of 3 patients with esophageal involvement developed an esophageal stricture, and none had esophageal fistulae. This patient was managed with intensified medical treatment and esophageal balloon dilatation.

Patients with UGICD are at greater risk of a more complicated disease course and bowel damage towards either stricturing or penetrating disease, more recurrent symptoms with frequent flare ups, more hospitalizations, and a greater chance of requiring bowel resection \[[@b12-ir-2019-00091],[@b30-ir-2019-00091]\]. Our results did not show that patients with UGICD are more prone to penetrating disease or have a greater likelihood of requiring surgical resections, presumably because of a lack of statistical power owing to the small sample size we examined.

We acknowledge that our study is limited by size and design. The lacking data of smoking was one of the limitations. The use of regular Upper GI endoscopy without chromoendoscopy or image-enhanced endoscopy may be an additional limitation in this study, because these techniques may improve the detectability of lesion for UGICD. Future prospective studies are needed to delineate the progression of UGICD over time and to study various possible predictors of outcomes.

In conclusion, in this cohort of patients with CD who had undergone diagnostic upper GI endoscopy, 24.4% of patients had involvement of the upper GI tract, regardless of age.
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![Focally enhanced gastritis. (A) Low power view of gastric body-type mucosa with patchy chronic gastritis (H&E, ×100). (B) High detail showing dense collection of chronic inflammatory cells around some antral glands with neutrophils infiltrating the glandular epithelium (H&E, ×200).](ir-2019-00091f1){#f1-ir-2019-00091}

![Non-caseating granuloma in duodenal biopsy. (A) Low power view (H&E, ×40) and (B) high power view (H&E, ×200).](ir-2019-00091f2){#f2-ir-2019-00091}

###### 

Baseline Characteristics of the Study Cohort

  Characteristic                            Value (n = 78)
  ----------------------------------------- ----------------
  Demographics                              
   Age (yr)                                 17.2 ± 8.7
   Female sex                               35 (44.9)
   Saudi nationality                        64 (82.0)
  Comorbidities                             
   Diabetes mellitus                        1 (1.3)
   Hypertension                             1 (1.3)
  Family history                            
   Family history of IBD                    5 (6.4)
   History of parental consanguinity        18 (23.0)
  Presenting symptoms                       
   Diarrhea                                 56 (72.0)
   Abdominal pain                           51 (65.4)
   Weight loss                              44 (56.4)
   Fatigue                                  39 (50.0)
   Vomiting                                 21 (26.9)
   Dysphagia                                2 (2.6)
  Montreal classification                   
   Age group                                
    A1 (\< 17 yr)                           44 (56.4)
    A2 (17--40 yr)                          31 (39.7)
    A3 (\> 40 yr)                           3 (3.8)
   Location                                 
    L1 (Terminal ileal)                     28 (35.9)
    L2 (Colonic)                            26 (33.3)
    L3 (Ileo-colonic)                       24 (30.8)
   Behavior                                 
    B1 (Non-stricturing, non-penetrating)   68 (87.2)
    B2 (Stricturing)                        7 (9.0)
    B3 (Penetrating)                        3 (3.8)
  Extraintestinal manifestations            
   Aphthous stomatitis                      8 (10.3)
   Perianal disease                         8 (10.3)
   Eye inflammation                         3 (3.8)
   Complications of CD                      24 (30.8)
  Laboratory investigations                 
   Leukocyte count (× 10^3^/μL)             9.0 ± 3.1
   Hemoglobin (g/dL)                        10.1 ± 3.1
   Platelets (× 10^3^/μL)                   507.6 ± 164.3
   Albumin (g/L)                            26.0 ± 7.7
   CRP (mg/L)                               49.5 ± 42.0

Values are presented as mean±SD or number (%).

###### 

Distribution of UGICD Histopathological Abnormalities According to Age

  Location UGICD   Age (yr)   Total (n = 19)   \% of the total cohort (n = 78)   *P*-value^[a](#tfn1-ir-2019-00091){ref-type="table-fn"}^   
  ---------------- ---------- ---------------- --------------------------------- ---------------------------------------------------------- -----
  Esophageal       3          0                3                                 3.8                                                        1.0
  Gastric          12         4                16                                20.5                                                       
  Duodenal         7          2                9                                 11.5                                                       
  Non UGICD        43                                                                                                                       

Fisher exact test.

UGICD, upper GI CD.

###### 

Upper GI Endoscopic Findings of Patients with UGICD (n=19)

  Endoscopic finding     Esophagus   Stomach    Duodenum
  ---------------------- ----------- ---------- -----------
  Normal                 16 (84.2)   3 (15.8)   12 (63.2)
  Erythema               0           5 (26.3)   5 (26.3)
  Erosions               0           8 (42.1)   0
  Aphthous ulcerations   2 (10.5)    2 (10.5)   2 (10.5)
  Stricture              1 (5.3)     1 (5.3)    0

Values are presented as number (%).

UGICD, upper GI CD.

###### 

Histopathological Findings of Patients with UGICD (n=19)

  Histopathological finding          No. (%)
  ---------------------------------- -----------
  Esophageal biopsy                  
   Chronic active esophagitis        3 (15.8)
  Gastric biopsy                     
   Chronic active gastritis          10 (52.6)
   Focal enhanced gastritis          6 (31.6)
  Duodenal biopsy                    
   Chronic active duodenitis         7 (36.8)
   Focal chronic active duodenitis   2 (10.5)
   Villous atrophy                   1 (5.3)
   Granuloma                         1 (5.3)

UGICD, upper GI CD.

###### 

Comparison between Patients with and without Upper GI Symptoms

  Characteristic                             Asymptomatic (n=9)   Symptomatic (n=10)   *P*-value^[a](#tfn2-ir-2019-00091){ref-type="table-fn"}^
  ------------------------------------------ -------------------- -------------------- ----------------------------------------------------------
  Baseline characteristics                                                             
   Sex                                                                                 0.65
    Male                                     6 (66.7)             5 (50.0)             
    Female                                   3 (33.3)             5 (50.0)             
   Nationality                                                                         0.58
    Saudi                                    8 (88.9)             7 (70.0)             
    Non Saudi                                1 (11.1)             3 (30.0)             
   Parental consanguinity                                                              0.58
    Yes                                      8 (88.9)             7 (70.0)             
    No                                       1 (11.1)             3 (30.0)             
  Montreal classification                                                              
   Age group                                                                           0.23
    A1 (\< 17 yr)                            6 (66.7)             3 (30.0)             
    A2 (17--40 yr)                           3 (33.3)             6 (60.0)             
    A3 (\> 40 yr)                            0                    1 (10.0)             
   Location                                                                            0.25
    L1 (Terminal ileal)                      7 (77.8)             4 (40.0)             
    L2 (Colonic)                             1 (11.1)             3 (30.0)             
    L3 (Ileo-colonic)                        1 (11.1)             3 (30.0)             
   Behavior                                                                            0.37
    B1 (Non-stricturing & non-penetrating)   8 (88.9)             9 (90.0)             
    B2 (Stricturing)                         0                    1 (10.0)             
    B3 (Penetrating)                         1 (11.1)             0                    
  Endoscopy findings                                                                   
   Esophageal                                                                          0.62
    Normal                                   8 (88.9)             8 (80.0)             
    Aphthous ulcers                          1 (11.1)             1 (10.0)             
    Stricture                                0                    1 (10.0)             
   Gastric                                                                             0.32
    Normal                                   3 (33.3)             0                    
    Erythema                                 2 (22.2)             3 (30.0)             
    Erosions                                 3 (33.3)             5 (50.0)             
    Aphthous ulcers                          1 (11.1)             1 (10.0)             
    Stricture                                0                    1 (10.0)             
   Duodenal                                                                            0.34
    Normal                                   6 (66.7)             6 (60.0)             
    Erythema                                 3 (33.3)             2 (20.0)             
    Aphthous ulcers                          0                    2 (20.0)             
  Histopathological findings                                                           
   Esophageal                                                                          0.78
    Normal                                   4 (44.4)             6 (60.0)             
    Chronic active duodenitis                4 (44.4)             3 (30.0)             
    Focal chronic active duodenitis          1 (11.1)             1 (10.0)             
   Gastric                                                                             0.71
    Normal                                   2 (22.2)             1 (10.0)             
    Chronic active gastritis                 4 (44.4)             6 (60.0)             
    Focal enhanced gastritis                 3 (33.3)             3 (30.0)             
   Duodenal                                                                            0.62
    Normal                                   8 (88.9)             8 (80.0)             
    Aphthous ulcers                          1 (11.1)             1 (10.0)             
    Stricture                                0                    1 (10.0)             

Values are presented as number (%).

Fisher exact test.

###### 

Bivariate Analysis Examining Associations with UGICD

  Variable                                      UGICD (n = 19)   Non UGICD (n = 59)   Total (n = 78)   *P*-value^[a](#tfn3-ir-2019-00091){ref-type="table-fn"}^
  --------------------------------------------- ---------------- -------------------- ---------------- ----------------------------------------------------------
  Sex                                                                                                  1.00
   Male                                         11 (57.9)        32 (54.2)            43 (55.1)        
   Female                                       8 (42.1)         27 (45.8)            35 (44.9)        
  History of parental consanguinity                                                                    1.00
   No                                           15 (78.9)        45 (76.3)            60 (76.9)        
   Yes                                          4 (21.1)         14 (23.7)            18 (23.1)        
  Age at diagnosis (Montreal)                                                                          0.65
   \< 17 yr                                     9 (47.4)         35 (59.3)            44 (56.4)        
   17--40 yr                                    9 (47.4)         22 (37.3)            31 (39.7)        
   \> 40 yr                                     1 (5.2)          2 (3.4)              3 (3.8)          
  Disease location (Montreal)                                                                          0.07
   L1 (Ileal)                                   11 (57.8)        17 (28.8)            28 (35.9)        
   L2 (Colonic)                                 4 (21.1)         22 (37.3)            26 (33.3)        
   L3 (Ileo-colonic)                            4 (21.1)         20 (33.9)            24 (30.8)        
  Disease behavior (Montreal)                                                                          0.77
   B1 (Non-stricturing & non-penetrating)       17 (89.4)        51 (86.4)            68 (87.2)        
   B2 (Stricturing)                             1 (5.3)          6 (10.2)             7 (9.0)          
   B3 (Penetrating)                             1 (5.3)          2 (3.4)              3 (3.8)          
  Symptoms                                                                                             1.00
   Diarrhea                                                                                            
    No                                          5 (26.3)         17 (28.8)            22 (28.2)        
    Yes                                         14 (73.7)        42 (71.2)            56 (71.8)        
   Fatigue                                                                                             1.00
    No                                          10 (52.6)        29 (49.2)            39 (50.0)        
    Yes                                         9 (47.4)         30 (50.8)            39 (50.0)        
   Dysphagia                                                                                           0.06
    No                                          17 (89.5)        59 (100)             76 (97.4)        
    Yes                                         2 (10.5)         0 (0)                2 (2.6)          
   Vomiting                                                                                            0.08
    No                                          11 (57.9)        46 (78)              57 (73.1)        
    Yes                                         8 (42.1)         13 (22)              21 (26.9)        
   Weight loss                                                                                         0.59
    No                                          7 (36.8)         27 (45.8)            34 (43.6)        
    Yes                                         12 (63.2)        32 (54.2)            44 (56.4)        
   Aphthous stomatitis (mouth sores)                                                                   1.00
    No                                          17 (89.5)        53 (89.8)            70 (89.7)        
    Yes                                         2 (10.5)         6 (10.2)             8 (10.3)         
   Eye inflammation (uveitis or sclerit         is)                                                    1.00
    No                                          19 (100)         56 (94.9)            75 (96.2)        
    Yes                                         0 (0)            3 (5.1)              3 (3.8)          
   Perianal disease (fissures, fistulas, anal   stenosis)                                              1.00
    No                                          17 (89.5)        53 (89.8)            70 (89.7)        
    Yes                                         2 (10.5)         6 (10.2)             8 (10.3)         
   Joints pain                                                                                         0.70
    No                                          17 (89.5)        51 (86.4)            68 (87.2)        
    Yes                                         2 (10.5)         8 (13.6)             10 (12.8)        
  Presence of complications                                                                            1.00
   No                                           13 (68.4)        41 (69.5)            54 (69.2)        
   Yes                                          6 (31.6)         18 (30.5)            24 (30.8)        

Values are presented as number (%).

Fisher exact test.
